Dave Kappos Speaks at the PTAB Bar Association’s 2022 Annual Conference
March 29, 2022
On March 24, 2022, Cravath partner David J. Kappos spoke at the Patent Trial and Appeal Board (“PTAB”) Bar Association’s 2022 Annual Conference, which was held from March 23‑25, 2022, in Washington, D.C. Dave participated virtually on a panel entitled “A Look Back at the First Decade of the AIA,” which discussed the origins and the first ten years of the American Invents Act. PTAB Bar Association’s Annual Conference features leading professionals discussing current issues in the Patent Trial and Appeal Board space.
Related Practices & Industries
Speakers
- Photo
-
-
J.D., 1990, University of California, Berkeley, School of Law
-
B.S., 1983, University of California, Davissumma cum laude
- New York
- California
- District of Columbia
Education
Admitted In
Related News & Insights
Deals & Cases
February 28, 2022
Viatris’s $3.335 Billion Combination of its Biosimilars Portfolio with Biocon Biologics
On February 28, 2022, Viatris Inc. (“Viatris”) announced that it reached a definitive agreement with Biocon Biologics Limited (“Biocon Biologics”) to contribute its biosimilars portfolio to Biocon Biologics, which will become a uniquely positioned, vertically integrated company expected to be a global biosimilars leader. Under the terms of the agreement, Viatris will contribute to Biocon Biologics its biosimilars portfolio and related commercial and operational capabilities, amounting to 2022 estimated revenue of approximately $875 million and 2022 estimated adjusted EBITDA of approximately $200 million, in exchange for pre-tax consideration of up to $3.335 billion, which represents a transaction multiple of 16.5x of estimated 2022 biosimilars adjusted EBITDA. Cravath is representing Viatris in connection with the transaction.
Deals & Cases
February 22, 2022
Taro’s Acquisition of Alchemee
On February 22, 2022, Taro Pharmaceutical Industries Ltd. (“Taro”), a multinational, science-based pharmaceutical company, and Galderma, the world’s largest independent dermatology company, announced they have signed a definitive agreement for Taro to acquire Alchemee, formerly The Proactiv Company, from Galderma. The agreement between Galderma and Taro includes Alchemee’s business and assets around the world, including the Proactiv brand. Cravath is representing Taro in connection with the transaction.
Deals & Cases
December 27, 2021
FactSet’s $1.9 Billion Acquisition of S&P Global’s CUSIP Global Services
On December 27, 2021, FactSet, a global provider of integrated financial information and analytical applications, announced that it has entered into a definitive agreement to acquire CUSIP Global Services, an operator of market standard security identifiers, from S&P Global for $1.925 billion in cash. Cravath is representing FactSet in connection with the transaction.
Deals & Cases
November 29, 2021
Elsevier’s Acquisition of Osmosis
On November 29, 2021, Elsevier, a global leader in research publishing and information analytics and part of RELX, announced that it has acquired Osmosis, a U.S.‑based visual learning education platform for millions of current and future healthcare professionals and their patients. RELX is a global provider of information‑based analytics and decision tools for professional and business customers. Cravath is representing RELX in connection with the transaction.
